Incidence, death and DALYs of TB, by age and sex in 2021. by Xue Li (285380)

Subjects:

Composition ratio of each types of tuberculosis ASDR in 1990 and 2021. by Xue Li (285380)

Subjects:

Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

Composition ratio of each types of tuberculosis ASMR in 1990 and 2021. by Xue Li (285380)

Subjects:

DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

General characteristics of relative handgrip strength at baseline. by Yeo Ju Sohn (18536198)

Subjects:

This dataset includes detailed information for 22,016 individuals. by Yeo Ju Sohn (18536198)

Subjects:

Flow diagram of participants meeting the inclusion and exclusion criteria. by Yeo Ju Sohn (18536198)

Subjects:

Initial participants by wave*. by Yeo Ju Sohn (18536198)

Subjects:

These files contain the STATA program codes used in the study. by Yeo Ju Sohn (18536198)

Subjects:

Generalized estimating equation model covariance structure analysis. by Yeo Ju Sohn (18536198)

Subjects:

Raw dataset collected from the KLoSA from 2006 to 2020. by Yeo Ju Sohn (18536198)

Subjects:

General characteristics of research participants. by Yeo Ju Sohn (18536198)

Subjects:

Generalized estimation equation model analysis of diabetes mellitus incidence according to relative handgrip strength. by Yeo Ju Sohn (18536198)

Subjects:

Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength. by Yeo Ju Sohn (18536198)

Subjects:

Genomic downregulation of TGF β1 production in monocytes obtained after RZV administration. Panel A. The heatmap shows 16 genes on the y axis whose accessibility significantly chan... by Michael J. Johnson (5818168)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

General characteristics of study subjects. by Soo-Hee Hwang (17767519)

“…Reductions in admission rates were greatest among men, those aged 55 and older, and people with medical aid. COVID-19 did not affect inpatient mortality (p = 0.9608), but in-hospital mortality decreased from 12% to 7% in the medical aid group.…”